Zobrazeno 1 - 10
of 17
pro vyhledávání: '"GREG ANGLIN"'
Autor:
BORIS CALDERON, GARRETT R. MULLINS, MICHAEL HODSDON, GRACE LI, GREG ANGLIN, SHWETA URVA, KAREN SCHNECK, JENNIFER N. BARDOS, RICARDO F. MARTINS, KATELYN BROWN
Publikováno v:
Diabetes. 71
Tirzepatide (TZP) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide (GLP) -1 receptor agonist developed for the treatment of type 2 diabetes. Patients receiving TZP may develop an immune response to the 39 amino a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1ae8c2f0730adbc31fda41fda722e43
https://doi.org/10.2337/db22-742-p
https://doi.org/10.2337/db22-742-p
Autor:
Brenda J. Crowe, Seta Shahin, Melvin Munsaka, Mary E. Nilsson, Wei Wang, Greg Ball, Greg Anglin
Publikováno v:
Statistics in Biopharmaceutical Research
article-version (VoR) Version of Record
article-version (VoR) Version of Record
In this paper, we provide guidance on how standard safety analyses and reporting of clinical trial safety data may need to be modified, given the potential impact of the COVID-19 pandemic. The impact could include missed visits, alternative methods f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4e1d40a9620b491493cbc32b4dca6e8
https://doi.org/10.1080/19466315.2020.1804444
https://doi.org/10.1080/19466315.2020.1804444
Autor:
James M. Martinez, Nada Hindiyeh, Sandra Garces, Greg Anglin, William Kielbasa, Kavita Kalidas, Brian A. Moser, Eric M. Pearlman, Michael E Hodsdon
Publikováno v:
Cephalalgia
Background This analysis characterizes the immunogenicity profile of galcanezumab, a humanized monoclonal antibody that selectively binds calcitonin gene-related peptide and inhibits its activity, in phase 3 migraine trials. Methods Immunogenicity da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23514b639128bff65a85e658c7542279
https://doi.org/10.1177/0333102420920642
https://doi.org/10.1177/0333102420920642
Autor:
Greg Anglin, T. Dwight McKinney, Katherine R. Tuttle, Kristine D. Harper, Jaime A. Davidson, Fady T. Botros
Publikováno v:
Diabetes, Obesity & Metabolism
Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist approved for the treatment of type 2 diabetes (T2D). Integrated data from 9 phase II and III trials in people with T2D (N = 6005) were used to evaluate the effects of dulaglutide o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a856df8507bb271ff2bf82f24165f70
http://europepmc.org/articles/PMC5347883
http://europepmc.org/articles/PMC5347883
Autor:
Robert J. Konrad, Kenneth F. Mace, Greg Anglin, Wolfgang Glaesner, Zachary Skrivanek, Kristine D. Harper, Zvonko Milicevic, Chrisanthi A. Karanikas
Publikováno v:
Diabetes, Obesity and Metabolism. 18:533-536
Therapeutic administration of peptides may result in anti-drug antibody (ADA) formation, hypersensitivity adverse events (AEs) and reduced efficacy. As a large peptide, the immunogenicity of once-weekly glucagon-like peptide-1 (GLP-1) receptor agonis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a153a018dd6df27d209e66c4e459ff9d
https://doi.org/10.1111/dom.12640
https://doi.org/10.1111/dom.12640
Publikováno v:
Therapeutic innovationregulatory science. 50(6)
A recent publication from Eli Lilly and Company provided guidance on incorporation of a structured benefit-risk assessment framework into Section 2.5.6 of the Clinical Overview of marketing authorization applications. Because a template alone cannot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c145b5a94bd03e6dc02918db602d75f
https://pubmed.ncbi.nlm.nih.gov/30231743
https://pubmed.ncbi.nlm.nih.gov/30231743
Autor:
Greg Anglin, Sherie A. Dowsett, Brenda J. Crowe, Ann Marie Hake, Roy Yaari, Eric Siemers, Christopher Carlson, Ludmila Kryzhanovskaya, Michael Case, David Perahia, Rashna Khanna, Gopalan Sethuraman
Publikováno v:
Alzheimer's & Dementia. 13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2cae468edfc81f6b595364faa44215b
https://doi.org/10.1016/j.jalz.2017.06.111
https://doi.org/10.1016/j.jalz.2017.06.111
Autor:
Anne M. Wolka, Shelby D. Reed, Michael Siegel, F. Reed Johnson, Greg Anglin, Angelyn O. Fairchild, Rebecca Noel
Publikováno v:
Therapeutic innovationregulatory science. 52(4)
Formal incorporation of patients' perspectives is becoming increasingly important in medical product development and decision making. This article shares practical advice regarding how patient advocacy organizations, the pharmaceutical industry, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b95973abcd55fbc7dd23e298b00c62b7
https://pubmed.ncbi.nlm.nih.gov/29714550
https://pubmed.ncbi.nlm.nih.gov/29714550
Autor:
Jamie S. Barkin, Greg Anglin, Zvonko Milicevic, Ingrid E. Hensley, Kristine D. Harper, Jean-Louis Frossard, Michael A. Nauck
Publikováno v:
Diabetes care. 40(5)
OBJECTIVE To assess the risk of acute pancreatitis during treatment with glucagon-like peptide 1 receptor agonist dulaglutide, placebo, and active comparators across phase 2/3 dulaglutide trials. RESEARCH DESIGN AND METHODS A total of 6,005 patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::478369b0afe64c4d103646bbb1cc0d50
https://pubmed.ncbi.nlm.nih.gov/28283565
https://pubmed.ncbi.nlm.nih.gov/28283565
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 91:3002-3010
Evidence exists for X-linked parent-of-origin effects in Turner syndrome, because phenotypic and cognitive profiles differ between 45,X(maternal) and 45,X(paternal) individuals.We evaluated the parent-of-origin effect of the intact X chromosome on sp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::275b63fe2fe24c56c2339053eb777f6d
https://doi.org/10.1210/jc.2006-0490
https://doi.org/10.1210/jc.2006-0490